 |
| CrossRef Text and Data Mining |
| Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining. |
| Real-world data for golimumab treatment in patients with ulcerative colitis in Japan: interim analysis in post-marketing surveillance |
| Shiro Nakamura, Teita Asano, Hiroaki Tsuchiya, Kanami Sugimoto, Yuya Imai, Seiji Yokoyama, Yasuo Suzuki |
|
DOI: https://doi.org/10.5217/ir.2021.00032 |
|
P466 Real-world effectiveness and safety of golimumab in patients with ulcerative colitis: 52-weeks of post-marketing surveillance data in Japan Journal of Crohn's and Colitis. 2022;16(Supplement_1):i439-i441  Real-world safety and efficacy of twice-daily budesonide 2-mg foam in patients with ulcerative colitis: interim analysis of post-marketing surveillance Expert Opinion on Pharmacotherapy. 2021;22(11):1505-1511 Clinical response among golimumab-treated Japanese patients with rheumatoid arthritis by number of previous biologic therapies: Real-world evidence from post-hoc analysis of post-marketing surveillance data Modern Rheumatology. 2020;31(3):566-574 P453 Golimumab in real-world practice in patients with ulcerative colitis: 2-year interim results from a non-interventional trial in Germany Journal of Crohn's and Colitis. 2019;13(Supplement_1):S337-S338 P350 Real-world data regarding treatment of ulcerative colitis patients with golimumab in Switzerland Journal of Crohn's and Colitis. 2019;13(Supplement_1):S278-S278 P433 A real-world observational study assessing treatment persistence in ulcerative colitis patients receiving anti-TNF treatment (golimumab or adalimumab) Journal of Crohn's and Colitis. 2020;14(Supplement_1):S394-S394 Real-World Safety and Effectiveness of Canakinumab in Patients with Tumour Necrosis Factor Receptor-Associated Periodic Syndrome or Hyperimmunoglobulinaemia D Syndrome: Interim Results from Post-Marketing Surveillance in Japan Modern Rheumatology. 2022; Exam 1: Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis and Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis Gastroenterology. 2014;146(1):e14-e15 Effect of Golimumab Dose Escalation in Japanese Patients With Rheumatoid Arthritis: Post-Hoc Analysis of Post-Marketing Surveillance Data Rheumatology and Therapy. 2020;7(2):311-325 Correction to: Effect of Golimumab Dose Escalation in Japanese Patients With Rheumatoid Arthritis: Post-Hoc Analysis of Post-Marketing Surveillance Data Rheumatology and Therapy. 2020;7(4):1053-1053 |
